RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor
The purpose of this study was to explore the safety and efficacy of raltitrexed combined with oxaplatin as second line treatment for advanced malignant biliary system tumor.
Cholangioadenoma
DRUG: Raltitrexed combined with oxaplatin
PFS（Progression Free Survival）, PFS is defined as the time interval from initiation of treatment to the first date of documented tumor progression or death from any cause, whichever occurs first., 24 months
ORR, Overall Response Rate, 24 months|OS, Overall Survival, 36 months|DCR, Disease Control Rate, 24 months|Qol ( quality of life ), EORTC-QLQ-C30 is a cancer-specific instrument, 24 months|AE, Adverse Event, 12 months
The purpose of this study was to explore the safety and efficacy of raltitrexed combined with oxaplatin as second line treatment for advanced malignant biliary system tumor. Single arm，phase II study for patients with cholangiocarcinoma or gallbladder carcinoma after first line treatment failure to explore effection and safety of raltitrexed combined with oxaplatin as second line treatment；Sample size：50.